ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

EXECUTIVE INTERVIEW: SeaStar CMO And Pediatric Specialist Talk About Promising Therapy To Treat Pediatric AKI

By Meg Flippin, Benzinga

The two were on hand to discuss QUELIMMUNE, SeaStar Medical’s humanitarian medical device that was granted U.S. FDA approval to treat pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition. Dr. Goldstein was the chief investigator for the two studies that led to the FDA approval. 

Pediatric AKI is a sudden episode of kidney failure that happens within a few hours or days. It can be brought on by several conditions including sepsis, severe trauma and surgery. AKI can cause hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from hyperinflammation in AKI can progress to other organs, such as the heart or liver and potentially lead to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, patients may face complications including chronic kidney disease or end-stage renal disease requiring dialysis. 

Treating The Untreatable 

There are about 4,000 cases of pediatric AKI each year in the U.S., Dr. Chung shared, and the mortality rate among those patients is high at 50%. QUELIMMUNE, which was granted approval under a Humanitarian Device Exemption (HDE) by the FDA in February 2024, was developed to treat AKI among children. 

“QUELIMMUNE is designed to target the innate immune response. When patients get very sick, it becomes very dysregulated and cells go haywire and trigger something called the cytokine storm,” said Dr. Chung in the interview. “The QUELIMMUNE device is designed specifically to target the cytokine storm at the source of the storm, and it is associated with really good outcomes, especially in the pediatric population where mortality was cut in half from 50% to 25%.”

That reduction in mortality is quite promising given that while there have been medical advances in treating AKI over the years, including targeted medications, nothing has been able to help patients with AKI so severe that it requires dialysis or inflammation so bad that it has increased the chance of death, Dr. Goldstein noted. But QUELIMMUNE proved very effective in trials, surprising even Dr. Goldstein, and that is why it received FDA approval and is being used in hospitals around the country. 

“What we saw as we started the initial trial is kids that had a 50% chance of mortality, not only did that go in half, but we saw a dramatic improvement almost in 24 to 48 hours, which was quite shocking to us frankly,” said Dr. Goldstein. What’s more, of the patients who survived, they were off dialysis sixty to ninety days later, something unheard of. Typically, 10-30% of pediatric patients who survive an AKI episode require chronic dialysis, Dr. Goldstein shared. “It’s a dramatic improvement that you see almost within the first one to two days. It is nothing I've seen before in clinical medicine in the last quarter century,” he stated further. 

Looking Beyond Pediatric AKI 

In addition to treating pediatric AKI, SeaStar is currently engaged in a trial evaluating the safety and efficacy of QUELIMMUNE for treating adult AKI. The study has over 100 patients enrolled, and the company is shooting for a total of 200. Beyond that, Dr. Chung said the idea is to use QUELIMMUNE for any condition in which the innate immune system is disturbed. 

“The therapy itself is organ- and disease-agnostic," said Dr. Chung, noting the company has six Breakthrough Device Designations from the FDA. BDD is designed to encourage speedier development of certain medical devices when there is a reasonable chance of providing a better treatment or diagnosis than the current standard of care. The BDD status is reserved for those diseases that are life-threatening or can cause irreversibly debilitating effects on patients. 

“Other disease states are definitely going to be next,” Dr. Chung told Benzinga.  

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.